Mainz Biomed (MYNZ) Competitors $1.66 -0.02 (-1.19%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$1.68 +0.02 (+1.20%) As of 09/12/2025 06:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock MYNZ vs. RVPH, ITRM, KZR, CLSD, ASBP, CASI, PMN, TENX, DARE, and BCABShould you be buying Mainz Biomed stock or one of its competitors? The main competitors of Mainz Biomed include Reviva Pharmaceuticals (RVPH), Iterum Therapeutics (ITRM), Kezar Life Sciences (KZR), Clearside Biomedical (CLSD), Aspire Biopharma (ASBP), CASI Pharmaceuticals (CASI), Promis Neurosciences (PMN), Tenax Therapeutics (TENX), Dare Bioscience (DARE), and BioAtla (BCAB). These companies are all part of the "pharmaceutical products" industry. Mainz Biomed vs. Its Competitors Reviva Pharmaceuticals Iterum Therapeutics Kezar Life Sciences Clearside Biomedical Aspire Biopharma CASI Pharmaceuticals Promis Neurosciences Tenax Therapeutics Dare Bioscience BioAtla Reviva Pharmaceuticals (NASDAQ:RVPH) and Mainz Biomed (NASDAQ:MYNZ) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, media sentiment, valuation and institutional ownership. Which has higher earnings and valuation, RVPH or MYNZ? Mainz Biomed has higher revenue and earnings than Reviva Pharmaceuticals. Reviva Pharmaceuticals is trading at a lower price-to-earnings ratio than Mainz Biomed, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioReviva PharmaceuticalsN/AN/A-$29.92M-$0.65-0.68Mainz Biomed$890K8.54-$21.65M-$65.60-0.03 Is RVPH or MYNZ more profitable? Company Net Margins Return on Equity Return on Assets Reviva PharmaceuticalsN/A N/A -259.17% Mainz Biomed N/A N/A N/A Do analysts recommend RVPH or MYNZ? Reviva Pharmaceuticals presently has a consensus target price of $5.20, suggesting a potential upside of 1,075.67%. Mainz Biomed has a consensus target price of $14.00, suggesting a potential upside of 743.37%. Given Reviva Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts plainly believe Reviva Pharmaceuticals is more favorable than Mainz Biomed.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Reviva Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.14Mainz Biomed 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Do institutionals and insiders hold more shares of RVPH or MYNZ? 63.2% of Reviva Pharmaceuticals shares are owned by institutional investors. 27.2% of Reviva Pharmaceuticals shares are owned by company insiders. Comparatively, 18.2% of Mainz Biomed shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Does the media favor RVPH or MYNZ? In the previous week, Reviva Pharmaceuticals and Reviva Pharmaceuticals both had 2 articles in the media. Mainz Biomed's average media sentiment score of 1.45 beat Reviva Pharmaceuticals' score of 0.59 indicating that Mainz Biomed is being referred to more favorably in the news media. Company Overall Sentiment Reviva Pharmaceuticals Positive Mainz Biomed Positive Which has more risk & volatility, RVPH or MYNZ? Reviva Pharmaceuticals has a beta of -0.04, meaning that its stock price is 104% less volatile than the S&P 500. Comparatively, Mainz Biomed has a beta of 0.25, meaning that its stock price is 75% less volatile than the S&P 500. SummaryReviva Pharmaceuticals beats Mainz Biomed on 7 of the 13 factors compared between the two stocks. Get Mainz Biomed News Delivered to You Automatically Sign up to receive the latest news and ratings for MYNZ and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MYNZ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MYNZ vs. The Competition Export to ExcelMetricMainz BiomedMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$7.69M$3.19B$5.84B$10.14BDividend YieldN/A2.30%5.68%4.60%P/E Ratio-0.0321.4375.4125.98Price / Sales8.54432.54515.86180.60Price / CashN/A46.6837.5660.44Price / Book0.649.6112.156.29Net Income-$21.65M-$53.29M$3.29B$271.07M7 Day Performance1.84%0.13%0.74%3.87%1 Month Performance-1.78%5.55%5.00%5.49%1 Year Performance-86.38%10.44%62.55%25.86% Mainz Biomed Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MYNZMainz Biomed3.1043 of 5 stars$1.66-1.2%$14.00+743.4%-86.4%$7.69M$890K-0.0330Positive NewsShort Interest ↓RVPHReviva Pharmaceuticals2.9916 of 5 stars$0.45-2.2%$5.20+1,055.6%-63.1%$30.60MN/A-0.695ITRMIterum Therapeutics3.0084 of 5 stars$0.68-2.2%$9.00+1,229.8%-37.4%$30.22MN/A-0.8010Positive NewsShort Interest ↓KZRKezar Life Sciences3.7568 of 5 stars$3.95-0.5%$9.00+127.8%-30.7%$28.93M$7M-0.4160News CoverageAnalyst UpgradeCLSDClearside Biomedical2.3561 of 5 stars$0.37-5.1%$4.20+1,042.9%-98.3%$28.85M$1.66M-0.9930Stock SplitGap DownHigh Trading VolumeASBPAspire BiopharmaN/A$0.58+3.4%N/AN/A$28.49MN/A0.00N/APositive NewsCASICASI Pharmaceuticals3.7774 of 5 stars$2.31-5.3%$4.00+73.2%-68.2%$28.41M$28.54M-0.80180PMNPromis Neurosciences3.6789 of 5 stars$0.54+2.7%$4.33+702.6%-63.9%$27.97MN/A0.005Positive NewsShort Interest ↓TENXTenax Therapeutics2.2593 of 5 stars$5.99+1.0%$17.00+183.8%+60.4%$27.33MN/A-6.519Positive NewsDAREDare Bioscience2.3228 of 5 stars$2.02-0.5%$12.00+494.1%-36.3%$27.23M$10K-0.9430Positive NewsShort Interest ↓BCABBioAtla2.4997 of 5 stars$0.46+8.5%$5.00+997.7%-57.2%$26.75M$11M-0.4160Gap Up Related Companies and Tools Related Companies Reviva Pharmaceuticals Alternatives Iterum Therapeutics Alternatives Kezar Life Sciences Alternatives Clearside Biomedical Alternatives Aspire Biopharma Alternatives CASI Pharmaceuticals Alternatives Promis Neurosciences Alternatives Tenax Therapeutics Alternatives Dare Bioscience Alternatives BioAtla Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MYNZ) was last updated on 9/14/2025 by MarketBeat.com Staff From Our PartnersNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredCollege grad makes $64,000 a monthA Wall Street legend just helped train our own proprietary AI system in the stock market (a project that took ...Stansberry Research | SponsoredWarren Buffett’s #1 AI Stock: Not Mag 7, And NOT on the NasdaqNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredApple’s falling behindApple just posted record-breaking results, yet its stock barely moved — because in today’s market, investors o...Porter & Company | Sponsored6-Figure Target for BTC by 2025The U.S. just announced it's putting GDP data directly onto Bitcoin and Ethereum blockchains. Could this spa...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mainz Biomed NV Please log in to your account or sign up in order to add this asset to your watchlist. Share Mainz Biomed With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MYNZ Stock Alerts